MAPK signaling pathway
The MAPK signaling pathway is a conserved intracellular signaling network that transduces extracellular and intracellular stimuli into coordinated cellular responses.
The MAPK signaling pathway is a conserved intracellular signaling network that transduces extracellular and intracellular stimuli into coordinated cellular responses. It is commonly discussed as a family of mitogen-activated protein kinase cascades, including ERK-, JNK-, and p38-related branches, which regulate processes such as cell proliferation, differentiation, stress responses, inflammation, apoptosis, and immune signaling. Because of this broad regulatory role, MAPK signaling is frequently implicated in cancer biology, inflammatory disease, tissue injury, and host defense.
In biomedical research, the pathway is often studied as a mechanistic node linking upstream receptors and stress signals to downstream transcriptional and post-translational responses. In the recent literature provided here, MAPK signaling appears as a target of pharmacologic modulation in psoriasis-like skin inflammation, melanoma cell migration and invasion, immune regulation in triple-negative breast cancer, anti-inflammatory compound screening, cardiovascular injury, and multi-pathway disease models involving NF-κB, Phosphatidylinositol 3-kinase (PI3K)/Protein kinase B (PKB), JAK-STAT, toll like receptor 4 (TLR4), and oxidative stress.
Where the papers sit
13 papers from the last 6 months study MAPK signaling pathway directly · updated from PubMed 3 Oct 2026
Study type 1 clinical trial · 1 human data · 10 preclinical · 1 unclassified
Themes no clear themes · 1 new direction
Those 13 do not share a common subject.
-
MAPK-associated signaling appears across unrelated cancer, tissue-injury, vascular, inflammatory and stroke studies. The set combines mechanistic experiments with network pharmacology, multi-omics, imaging and drug-repurposing analyses rather than a shared disease question. Reported interventions range from trametinib and nilotinib to botanical preparations and targets such as BRAF, PON1 and GAB3. These links do not establish a common therapeutic direction or coherent evidence base.
MAPK activation can function as a trigger of immunogenic tumor-cell death that enhances immunotherapy
Nilotinib in melanoma models was found to repress ATP7A through ETV1, cause mitochondrial copper accumulation, and activate MAPK through ERK2 phosphorylation, thereby inducing immunogenic cuproptosis and improving anti-PD-1 efficacy across several melanoma models 42486098Jul. This assigns MAPK signaling a role outside the set’s usual pattern of driving disease progression or serving as a pathway to inhibit: its activation becomes part of the mechanism that makes tumor cells immunogenic and potentiates immunotherapy.
Papers
The 13 papers from the last 6 months that study MAPK signaling pathway directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
No clear themes (13)
- Exploring the mechanism of Panax notoginseng injection in the treatment of skin wound based on network pharmacology and experimental verification. Journal of molecular histology · 4 Sept 2026 PMID 42696214
- MRI-Based Deep Learning Guides Multi-Omics Discovery of NBPF4 as a Therapeutic Target for Breast Cancer Lymph Node Metastasis. Research (Washington, D.C.) · 25 Aug 2026 PMID 42639147
- Polygonum cuspidatum Exosome-Like Nanovesicles Alleviate Hypoxic Pulmonary Hypertension by Stabilizing PON1 to Inhibit MAPK-Mediated PASMC Phenotypic Switching. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 15 Aug 2026 PMID 42603092
- Integrated computational and preclinical evaluation of drug repurposing candidates for KRAS-mutant non-small cell lung cancer. Scientific reports · 13 Aug 2026 PMID 42595781
- Nilotinib induces immunogenic cuproptosis to potentiate cancer immunotherapy. Cell reports. Medicine · 22 Jul 2026 PMID 42486098
- Experimental investigation and network pharmacology-based analysis of the anticancer mechanisms of Fei Jin Sheng formula. Journal of molecular histology · 16 Jul 2026 PMID 42461333
- Trametinib for NRAS-mutated tumors: Results from the Drug Rediscovery Protocol. European journal of cancer (Oxford, England : 1990) · 26 Jun 2026 PMID 42361675
- A novel m7G RNA methylation-related signature associated with MAPK signaling pathways in acute ischemic stroke. PloS one · 23 Jun 2026 PMID 42335089
- Design, Synthesis, and Evaluation of Novel Syncarpic Acid Derivatives as Potential Anti-Inflammatory Agents. ChemMedChem · 15 May 2026 PMID 42136121
- ZDHHC5-mediated BRAF palmitoylation activates the MAPK pathway and drives cholangiocarcinoma progression. Cancer letters · 14 May 2026 PMID 42134490
- Establishment of an integrated profiling-fingerprinting-chemometrics strategy for quality control and mechanistic investigation of Fuhuo Capsule. Journal of chromatography. A · 13 May 2026 PMID 42127880
- Tranexamic acid protects human dermal fibroblasts from D-galactose-induced senescence via the GPR30/MAPK pathway. Annals of medicine · 30 Apr 2026 PMID 42059427
- GAB3 suppresses lung adenocarcinoma progression by inhibiting the MAPK signaling and potentiating CD8+ T cell immunity. Cancer letters · 24 Apr 2026 PMID 42031161
By study type
Clinical trials (1)
- Tranexamic acid protects human dermal fibroblasts from D-galactose-induced senescence via the GPR30/MAPK pathway. Annals of medicine · 30 Apr 2026 PMID 42059427
Human data, design not indexed (1)
- Trametinib for NRAS-mutated tumors: Results from the Drug Rediscovery Protocol. European journal of cancer (Oxford, England : 1990) · 26 Jun 2026 PMID 42361675
Preclinical: animal, cell and lab studies (10)
- Exploring the mechanism of Panax notoginseng injection in the treatment of skin wound based on network pharmacology and experimental verification. Journal of molecular histology · 4 Sept 2026 PMID 42696214
- Polygonum cuspidatum Exosome-Like Nanovesicles Alleviate Hypoxic Pulmonary Hypertension by Stabilizing PON1 to Inhibit MAPK-Mediated PASMC Phenotypic Switching. FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 15 Aug 2026 PMID 42603092
- Integrated computational and preclinical evaluation of drug repurposing candidates for KRAS-mutant non-small cell lung cancer. Scientific reports · 13 Aug 2026 PMID 42595781
- Nilotinib induces immunogenic cuproptosis to potentiate cancer immunotherapy. Cell reports. Medicine · 22 Jul 2026 PMID 42486098
- Experimental investigation and network pharmacology-based analysis of the anticancer mechanisms of Fei Jin Sheng formula. Journal of molecular histology · 16 Jul 2026 PMID 42461333
- A novel m7G RNA methylation-related signature associated with MAPK signaling pathways in acute ischemic stroke. PloS one · 23 Jun 2026 PMID 42335089
- Design, Synthesis, and Evaluation of Novel Syncarpic Acid Derivatives as Potential Anti-Inflammatory Agents. ChemMedChem · 15 May 2026 PMID 42136121
- ZDHHC5-mediated BRAF palmitoylation activates the MAPK pathway and drives cholangiocarcinoma progression. Cancer letters · 14 May 2026 PMID 42134490
- Establishment of an integrated profiling-fingerprinting-chemometrics strategy for quality control and mechanistic investigation of Fuhuo Capsule. Journal of chromatography. A · 13 May 2026 PMID 42127880
- GAB3 suppresses lung adenocarcinoma progression by inhibiting the MAPK signaling and potentiating CD8+ T cell immunity. Cancer letters · 24 Apr 2026 PMID 42031161
Unclassified: not yet indexed with MeSH (1)
- MRI-Based Deep Learning Guides Multi-Omics Discovery of NBPF4 as a Therapeutic Target for Breast Cancer Lymph Node Metastasis. Research (Washington, D.C.) · 25 Aug 2026 PMID 42639147
Written from 13 PubMed abstracts, each one listed by PMID above. Published: 2026-06-16. Last written: 2026-09-06 by GPT. Drafted by language models from published abstracts; not medical advice.